|Videos|November 16, 2022
Defining SARS-CoV-2 Bivalent Vaccines and Optimizing Protection Through Vaccination
Wendy Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP; Jacinda Abdul-Mutakabbir, PharmD; and Rodney E. Rohde, PhD, MS, SM(ASCP)CM, SVCM, MBCM, FACSc; review what encompasses a bivalent vaccine and give their perspective on how to communicate the role of the vaccine in optimizing protection for patients.
Advertisement
Advertisement
Related to this article
Garlic has a long history in traditional medicine, but evidence for its benefits varies by preparation, and patients taking medications that increase bleeding risk should use it with caution.
About 89% of Americans live within 5 miles of a pharmacy, but proximity says little about whether they can afford their medications or get real counseling.
ASRA’s cancer pain programming highlights opportunities for pharmacists to individualize opioid therapy, improve medication transitions, and connect patients with evidence-based complementary care.
The costs to patients, their families, their workplaces, and their communities go well beyond dollars and cents.
Across every setting, the pharmacist's role is to build reliable systems around patients so stroke prevention remains safe and sustainable across the care continuum.
The once-daily oral CSF-1R inhibitor was approved based on the phase 3 MANEUVER trial, which showed gains in tumor response, pain, and joint function.
SCOUT-HCM data show LVOT gradient reductions persisted, patients switching from placebo responded similarly, and no patient had LVEF below 50%.
On NET Cancer Day, a return visit for an over-the-counter antidiarrheal illustrates how pharmacists can identify a symptom pattern and help patients seek evaluation.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Oral PCSK9 Inhibitor Enlicitide Sustains LDL-C Reductions
2
FDA Requires Class-Wide GLP-1 RA Labeling Changes for Potential NAION Risk
3
Lilly–Hims & Hers GLP-1 Deal Tests Whether Convenience Can Deliver Continuity of Care
4
FDA Approves Pimicotinib for Tenosynovial Giant Cell Tumor
5